Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hepatocellular Carcinoma
Clinical trial register · United States · industry-sponsored

Hepatocellular Carcinoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 35 Florida 24 Arizona 15 Illinois 12 New York 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca8 AbbVie3 Teclison Ltd.2 Replimune, Inc.2 ImmunoVaccine Technologies, Inc. (IMV Inc.)1
State
California35 Florida24 Arizona15 Illinois12 New York11
All 38 states
Target enrolment
to

Hepatocellular Carcinoma trials in the USA

38 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
NCT06887348Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Replimune, Inc.
Observational
50
California
2025-12-12
Recruiting
Pfizer
Phase 1/2
138
California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Ohio
2025-12-01
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
AstraZeneca
Phase 3
1,220
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii
2025-05-06
Recruiting
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
Bayer
Phase 1
148
Alabama, California, Florida, Tennessee
2025-02-28
Active, closed
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Recruiting
Replimune, Inc.
Phase 2
60
California, Florida, Maryland, New York, Pennsylvania, Tennessee, Texas
2024-08-01
Active, closed
Genentech, Inc.
Phase 2
30
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2024-07-15
Active, closed
AbbVie
Phase 2/3
89
California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas
2024-01-11
Active, closed
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Active, closed
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740Advanced Solid Tumor, Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
Phase 1
70
Arizona, California, Florida, Minnesota, Virginia
2023-12-04
Recruiting
AbbVie
Phase 1
325
California, Colorado, Florida, Illinois, Michigan, Missouri, New York, North Carolina
2023-11-09
Active, closed
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565Hepatocellular Carcinoma
Boston Scientific Corporation
Phase 2
100
California, District of Columbia, Florida, Illinois, Louisiana, Minnesota, Missouri, New York
2023-11-03
Active, closed
AbbVie
Phase 2
130
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Massachusetts
2023-09-21
Active, closed
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NCT05953337Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
ABK Biomedical
Not applicable
120
Arizona, California, Florida, Georgia, Illinois, Iowa, Kentucky, Louisiana
2023-09-21
Active, closed
Hoffmann-La Roche
Phase 3
687
Arkansas, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2023-09-14
Active, closed
AstraZeneca
Phase 2
294
Alabama, California, Kansas, New York
2023-04-24
Recruiting
Tvardi Therapeutics, Incorporated
Phase 1/2
193
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Michigan, Missouri
2023-03-23
Recruiting
Can-Fite BioPharma
Phase 3
471
Texas
2023-03-15
Active, closed
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Sotio Biotech Inc.
Phase 1/2
7
California, Texas, Washington, Wisconsin
2022-10-26
Active, closed
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Georgia, Maryland, New Mexico, New York, Tennessee
2022-03-28
Recruiting
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
NCT04864054Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
Eureka Therapeutics Inc.
Phase 1/2
60
California, Kansas, New York, Oregon, Texas, Washington
2022-03-11
Recruiting
Multi-analyte Blood Test Clinical Trial
NCT05199259Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Helio Genomics
Observational
1,200
California, Florida, Texas
2022-03-01
Active, closed
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
Exact Sciences Corporation
Observational
2,990
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa
2021-07-26
Active, closed
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
NCT04572633Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
HistoSonics, Inc.
Not applicable
47
Florida, Illinois, Kansas, Michigan, Wisconsin
2021-01-27
Recruiting
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
BioEclipse Therapeutics
Phase 1
60
Arizona, California
2021-01-08
Active, closed
CStone Pharmaceuticals
Phase 3
534
California, Maryland, Massachusetts, New York
2019-12-13
Active, closed
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT03916627Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
65
New York
2019-07-23
Active, closed
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
184
Arizona, California, Florida, Georgia, Kentucky, Louisiana, Minnesota, New Mexico
2018-12-21
Active, closed
AstraZeneca
Phase 3
724
California, District of Columbia, Florida, Hawaii, Illinois, Louisiana, Michigan, Minnesota
2018-11-30
Active, closed
Exelixis
Phase 3
837
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts
2018-06-10
Active, closed
Bristol-Myers Squibb
Phase 3
545
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana
2018-04-18
Active, closed
AstraZeneca
Phase 3
1,324
California, District of Columbia, Florida, Kansas, Maryland, Michigan, Minnesota, New York
2017-10-11
Recruiting
Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867Hepatocellular Carcinoma, Gastric Cancer
DrugOpdivo
Teclison Ltd.
Phase 2
54
California, Oklahoma, Wisconsin
2017-07-01
Active, closed
MedImmune LLC
Phase 2
433
Arizona, California, Connecticut, Florida, Indiana, Massachusetts, New York, North Carolina
2015-10-19
Recruiting
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
NCT02174549Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
DrugTirapazamine
Teclison Ltd.
Phase 1/2
25
California, Pennsylvania
2014-09
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/hepatocellular-carcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies listing the condition Hepatocellular Carcinoma.

How many Hepatocellular Carcinoma trials are recruiting in the US?

15 of the 38 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 22 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hepatocellular Carcinoma), 38 studies
PhaseStudiesRecruitingShare
Phase 210226.3%
Phase 39223.7%
Phase 1/27518.4%
Phase 15413.2%
Observational4210.5%
Not applicable205.3%
Phase 2/3102.6%

Most active sponsors

Lead sponsors with the most studies (Hepatocellular Carcinoma)
Lead sponsorStudiesRecruiting
AstraZeneca82
AbbVie31
Replimune, Inc.22
Teclison Ltd.22
ABK Biomedical10
Bayer11
BioEclipse Therapeutics11
Boston Scientific Corporation10
Bristol-Myers Squibb10
Can-Fite BioPharma11

Top states

Top states (Hepatocellular Carcinoma), by number of studies with a site there
StateStudies
California35
Florida24
Arizona15
Illinois12
New York11
District of Columbia10
Georgia9
Kansas9
Minnesota9
Louisiana8
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.